Tree-Leaf Flavonoid Eases Parkinson’s Symptoms in Mice via Gut Bacteria

Parkinson's disease has never been just a brain disease. Patients often develop gut symptoms, like constipation, years before the tremors and slowed movement that define the condition, and researchers increasingly look to the trillions of bacteria living in the gut for clues, and maybe eventually treatments. A new mouse study, published in the Journal of Future Foods, adds a fresh thread to that story: a flavonoid (a type of plant antioxidant compound) extracted from the leaves of Cyclocarya paliurus, a tree long used in Chinese folk medicine, protected dopamine-producing brain cells in a chemically induced mouse model of Parkinson's disease, while reshaping the animals' gut bacteria and a metabolic pathway tied to the amino acid tryptophan. It is early, animal-only work, but it adds detail to the developing idea that the gut and the brain communicate in ways that matter for this disease.

Key takeaways

• In mice with chemically induced Parkinson's-like brain damage, a flavonoid extract from Cyclocarya paliurus leaves (CPF) improved motor function, protected dopamine-producing neurons, and reduced brain inflammation markers.
• CPF also shifted the mice's gut bacteria, boosting a genus called Lactobacillus and reducing two genera linked to inflammation, changes that statistically tracked with how well the brain markers looked.
• Fecal chemical analysis flagged tryptophan metabolism (the pathway that also produces indole and kynurenine) as the most affected chemical pathway in CPF-treated mice.
• This is mouse-only, chemically induced disease research, and the authors themselves say the gut-bacteria link is correlational, not proven causal.

Cyclocarya Paliurus Flavonoids Protect Dopamine Neurons in Mice

Researchers at Jiangxi Agricultural University in China extracted a flavonoid-rich compound, called CPF, from the leaves of Cyclocarya paliurus and tested it in mice with MPTP-induced Parkinson's disease, a standard lab model that kills dopamine-producing neurons and produces Parkinson's-like movement problems. Untreated, MPTP-exposed mice took 46.89% longer to climb down a test pole than healthy mice, a standard measure of motor slowing, and lost an estimated 24.19% of dopamine-marking neurons in one brain region (the substantia nigra) and 68.94% in another (the striatum). Mice given CPF, especially at medium and high doses, moved down the pole faster and showed higher levels of the same dopamine-neuron marker, tyrosine hydroxylase (TH), in both regions. CPF-treated mice also had lower blood levels of several inflammatory signaling proteins (IL-1B, IL-6, TNF-alpha) and higher levels of an anti-inflammatory one (IL-10), alongside markers showing less oxidative cell damage.

Why This Gut-Brain Link Matters for Parkinson's Disease

Parkinson's disease is projected to affect an estimated 25.2 million people worldwide by 2050, according to a 2025 global burden analysis the study's authors cite, a sharp rise driven mostly by an aging population. For years, clinicians have noted that gastrointestinal problems often show up in Parkinson's patients before the classic motor symptoms do, an observation that helped drive the broader gut-brain axis research into the disease. This study adds to that picture from the microbiome side: the mice's gut bacteria composition, not just their brain chemistry, shifted alongside the disease and its treatment. That matters for anyone following Parkinson's research or managing risk factors, because it suggests the gut is not a passive bystander but part of the biology researchers are trying to understand and, eventually, intervene on.

MPTP Mouse Model Tested Six Treatment Groups

The researchers used 60 mice split into six groups of ten: an untreated control group, an MPTP-only "model" group, a group given the approved Parkinson's drug rasagiline, and three groups given low, medium, or high doses of CPF (100, 200, or 400 milligrams per kilogram of body weight). All animals received their assigned treatment by gavage for 14 days, and from day eight onward, every group except the control received daily MPTP injections for a week to induce Parkinson's-like brain damage. The team then measured motor behavior, blood markers of inflammation and oxidative stress, brain tissue markers of neuron loss and immune-cell activation, gut bacteria composition (through genetic sequencing of fecal samples), and the chemical profile of the mice's feces.

What the Gut Bacteria Shift Might Mean

Sequencing showed that MPTP itself altered the mix of gut bacteria: it roughly quadrupled the relative abundance of one genus, Odoribacter (up 443%), and nearly tripled another, Alistipes (up 183%), both linked in this study to more brain inflammation. CPF treatment brought both back toward control-group levels. CPF also raised the abundance of Lactobacillus and a related genus, Ligilactobacillus, both considered generally beneficial gut bacteria; the higher the Ligilactobacillus level, the more of the dopamine-neuron marker TH the mice's brains showed, a statistical association, not proof that one caused the other. Separately, chemical analysis of the mice's feces found that tryptophan metabolism, the pathway that also produces the neuroactive compounds indole and kynurenine, was the single most affected chemical pathway in every CPF-dosed group. Some gut bacteria, including certain Lactobacillus and Bifidobacterium species, convert tryptophan into indole compounds that act on the gut's immune system, and separately, tryptophan breaks down into kynurenine-pathway compounds implicated in Parkinson's-related brain inflammation. For a reader managing their own gut health, the honest takeaway is that this study links a gut chemistry change to a brain outcome in mice, not that a supplement or diet change protects the human brain; that step has not been tested.

Correlation, Not Proof, Links Gut Bacteria to Brain Protection

The study's own authors are explicit about this limit: the gut microbiota changes and the neuroprotective effects were correlated, not shown to be causally linked. They did not directly measure indole or kynurenine-pathway chemicals in blood or brain tissue, only inferred the pathway's involvement from a fecal chemical-pathway analysis, and they call their own microbiome findings "hypothesis-generating" rather than conclusive. Group sizes also varied by test: behavioral tests used 10 mice per group, but molecular and gut-microbiota assays used three to four per group, typical for exploratory mouse studies but still small. MPTP-induced brain damage is also a chemical model of Parkinson's, not the disease as it develops naturally in people, so how closely the biology matches human Parkinson's remains uncertain.

Next Steps for Confirming a Gut-Brain Pathway

To move from correlation to causation, the researchers say the next step is to directly measure tryptophan-pathway chemicals in blood and brain tissue, test the relevant enzymes, and transplant gut bacteria from CPF-treated mice into germ-free mice, the kind of test that previously showed gut microbiota can regulate motor deficits in a different Parkinson's mouse model. None of that work has been done yet, and the paper gives no timeline for it or for any human research.

Common Questions

What is Cyclocarya paliurus? It is a tree native to China whose leaves have long been used in folk medicine and are also studied for effects on blood sugar; this study tested a flavonoid-rich extract from those leaves.

Does this mean the extract could treat Parkinson's disease in people? No. Every result here comes from a mouse model of chemically induced brain damage, and the authors have not tested the extract, or any human dose of it, in people with Parkinson's disease.

What is the gut-brain axis and why does it come up in Parkinson's research? It refers to the two-way communication between gut bacteria and the nervous system. It comes up in Parkinson's research partly because gut symptoms often precede motor symptoms in patients, and animal studies like this one keep finding that gut bacteria composition tracks with brain-related outcomes.

Did the researchers prove gut bacteria caused the brain protection? No. They found a statistical association between certain gut bacteria and brain markers, and they say directly that establishing cause and effect would require further experiments, such as transplanting the bacteria into other mice, which they have not yet done.

References

Yi Han, Lirong Shen, Lingli Chen, et al. (2026). Cyclocarya paliurus flavonoids alleviate MPTP-induced Parkinson’s disease in mice via gut microbiota modulation and tryptophan metabolism. Journal of Future Foods. https://doi.org/10.1016/j.jfutfo.2026.09.008